Clinical Trial Detail

NCT ID NCT01980888
Title Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences
Indications

chronic lymphocytic leukemia

Therapies

Bendamustine + Idelalisib + Rituximab

Age Groups: adult

No variant requirements are available.